ASH 2023 | Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses a study evaluating the comparative effectiveness of ibrutinib flexible dosing strategies on time to next treatment (TTNT). This was a large community-based study demonstrating that dose adjustment of first-line single-agent ibrutinib treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) is not associated with an increased risk of initiating next line of therapy compared to continuous standard dose treatment. These findings suggest that a flexible dosing approach may be an effective option to maintain an optimal balance of clinical therapeutic efficacy and safety for patients with CLL/SLL in the first-line setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: AstraZeneca, Janssen, Pharmacyclics, Kite pharma, BMS, Epizyme; Speakers Bureau: TG Therapeutics, Genentech/Roche, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics; Honoraria: Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics, Morp; Membership on an entity’s Board of Directors or advisory committees: Roche NHL solutions panel; Consultancy: Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics.
